Robert M. Califf

Professor of Medicine
Donald F. Fortin, M.D. Professor of Cardiology, in the School of Medicine
Member of the Duke Clinical Research Institute
Campus mail 100 Trent Drive, Suite401, Davison Building, Durham, NC 27710
Phone (919) 668-9222
Email address robert.califf@duke.edu

Robert Califf, MD MACC, is the Donald F. Fortin, MD, Professor of Cardiology. He is also Professor of Medicine in the Division of Cardiology and remains a practicing cardiologist. Dr. Califf was the Commissioner of Food and Drugs in 2016-2017 and  Deputy Commissioner for Medical Products and Tobacco from February 2015 until his appointment as Commissioner in February 2016. Prior to joining the FDA, Dr. Califf was a professor of medicine and vice chancellor for clinical and translational research at Duke University. He also served as director of the Duke Translational Medicine Institute and founding director of the Duke Clinical Research Institute. A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,200 publications in the peer-reviewed literature.

Dr. Califf is a Member of the National Academy of Medicine (formerly known as the Institute of Medicine (IOM)) in 2016, one of the highest honors in the fields of health and medicine. Dr. Califf has served on numerous IOM committees, and he has served as a member of the FDA Cardiorenal Advisory Panel and FDA Science Board's Subcommittee on Science and Technology. Dr. Califf has also served on the Board of Scientific Counselors for the National Library of Medicine, as well as on advisory committees for the National Cancer Institute, the National Heart, Lung, and Blood Institute, the National Institute of Environmental Health Sciences and the Council of the National Institute on Aging.

He has led major initiatives aimed at improving methods and infrastructure for clinical research, including the Clinical Trials Transformation Initiative (CTTI), a public-private partnership co-founded by the FDA and Duke. He also served as the principal investigator for Duke's Clinical and Translational Science Award and the NIH Health Care Systems Research Collaboratory coordinating center and co-PI of the Patient Centered Outcomes Research Institute Network.

Associated Faculty Labs

Publications

Holman, RR, Sourij, H, and Califf, RM. "Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes." Lancet (London, England) 383, no. 9933 (June 2014): 2008-2017. (Review)

PMID
24910232
Full Text

"Department of Error." The Lancet 383, no. 9936 (June 2014): 2212-2212.

Full Text

Sherwood, MW, Douketis, JD, Patel, MR, Piccini, JP, Hellkamp, AS, Lokhnygina, Y, Spyropoulos, AC, Hankey, GJ, Singer, DE, Nessel, CC, Mahaffey, KW, Fox, KAA, Califf, RM, and Becker, RC. "Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: Results from the rivaroxaban once daily, oral, direct factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)." Circulation 129, no. 18 (May 6, 2014): 1850-1859.

Full Text

Sherwood, MW, Douketis, JD, Patel, MR, Piccini, JP, Hellkamp, AS, Lokhnygina, Y, Spyropoulos, AC, Hankey, GJ, Singer, DE, Nessel, CC, Mahaffey, KW, Fox, KAA, Califf, RM, Becker, RC, and ROCKET AF Investigators, . "Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)." Circulation 129, no. 18 (May 2014): 1850-1859.

PMID
24552831
Full Text

Kalogeropoulos, AP, Tang, WHW, Hsu, A, Felker, GM, Hernandez, AF, Troughton, RW, Voors, AA, Anker, SD, Metra, M, McMurray, JJV, Massie, BM, Ezekowitz, JA, Califf, RM, O'Connor, CM, Starling, RC, and Butler, J. "High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial." Journal of Cardiac Failure 20, no. 5 (May 2014): 319-326.

PMID
24530944
Full Text

Hankey, GJ, Stevens, SR, Piccini, JP, Lokhnygina, Y, Mahaffey, KW, Halperin, JL, Patel, MR, Breithardt, G, Singer, DE, Becker, RC, Berkowitz, SD, Paolini, JF, Nessel, CC, Hacke, W, Fox, KAA, Califf, RM, and ROCKET AF Steering Committee and Investigators, . "Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation." Stroke 45, no. 5 (May 2014): 1304-1312.

PMID
24743444
Full Text

Califf, RM. "The Patient-Centered Outcomes Research Network: a national infrastructure for comparative effectiveness research." North Carolina Medical Journal 75, no. 3 (May 2014): 204-210.

PMID
24830497
Scholars@Duke

Inrig, JK, Califf, RM, Tasneem, A, Vegunta, RK, Molina, C, Stanifer, JW, Chiswell, K, and Patel, UD. "The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov." American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation 63, no. 5 (May 2014): 771-780. (Review)

PMID
24315119
Full Text

Huffman, KM, Sun, J-L, Thomas, L, Bales, CW, Califf, RM, Yates, T, Davies, MJ, Holman, RR, McMurray, JJV, Bethel, MA, Tuomilehto, J, Haffner, SM, and Kraus, WE. "Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR." Metabolism: Clinical and Experimental 63, no. 4 (April 2014): 554-561.

PMID
24559843
Full Text

Kunadian, V, Giugliano, RP, Newby, LK, Zorkun, C, Guo, J, Bagai, A, Montalescot, G, Braunwald, E, Califf, RM, Van de Werf, F, Armstrong, PW, Harrington, R, and Gibson, CM. "Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial)." The American Journal of Cardiology 113, no. 8 (April 2014): 1297-1305.

PMID
24607027
Full Text

Pages